Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers
Date:12/13/2011

CAMBRIDGE, Mass., Dec. 13, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical study combining MM-121, a fully human monoclonal antibody that targets ErbB3, with cetuximab (Erbitux®) and irinotecan (Camptosar®) in patients with advanced cancers.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

The Phase 1 study evaluates the safety and pharmacokinetics of MM-121 when administered in combination with cetuximab and irinotecan in patients with advanced colorectal cancer, squamous cell head and neck cancer, non-small cell lung cancer, triple negative breast cancer, or other types of solid tumors that depend on epidermal growth factor receptor (EGFR) activity. Multiple centers across the United States are expected to participate in this study. The first patient was enrolled at the Huntsman Cancer Institute at the University of Utah in Salt Lake City.

Merrimack entered into an exclusive, global collaboration and licensing agreement with Sanofi for MM-121 in 2009.

About Merrimack
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process.  Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth expected to enter clinical development by early 2012.

Contact:  Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043, kgallagher@merrimackpharma.com
Betsy Stevenson, RaymondStevenson Healthcare Communicat
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
2. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
3. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
4. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
5. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
6. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
7. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
8. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
10. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014  Australian drug delivery company, Phosphagenics ... has raised A$19.3 million via a placement of A$16.3 ... , the U.S., Asia and ... a share purchase plan (SPP) to be offered to ... made in two tranches. "This capital raising ...
(Date:7/11/2014)... New York , July 11, 2014 ... by Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic ... Size, Share, Growth, Trends and Forecast, 2013-2019" the global ... in 2012 and is expected to grow at a ... an estimated value of USD 36.9 billion in 2019. ...
(Date:7/11/2014)... 2014  Veran Medical Technologies, a U.S. ... positive, cost-effective final results for the initial ... SPiNPerc endobronchial percutaneous biopsy study results support ... biopsy when a traditional bronchoscopic method is ... positive financial outcomes when more can be ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Veran Medical Publishes Lung Cancer Patient Management Study 2
... , , ROCHESTER, Minn., July 7 ... examined in a series of articles and editorials in the ... subject is especially timely. As the immense challenges, including potential ... these articles offer crucial overview, direction and optimism. , ...
... highlights from the June issue of Mayo Clinic Women,s ... you wish. Mayo Clinic Women,s HealthSource ... fee. Include the following subscription information as your editorial policies ... for subscription information, 1-800-876-8633, extension 9751. , , ...
Cached Medicine Technology:Mayo Clinic Proceedings: A Comprehensive Review of Addiction to Prescription Painkillers Among Patients and Physicians 2Mayo Clinic Proceedings: A Comprehensive Review of Addiction to Prescription Painkillers Among Patients and Physicians 3Mayo Clinic Proceedings: A Comprehensive Review of Addiction to Prescription Painkillers Among Patients and Physicians 4June 2009 Mayo Clinic Women's HealthSource Highlights Summer Skin Problems, Low Vision and Pilates 2June 2009 Mayo Clinic Women's HealthSource Highlights Summer Skin Problems, Low Vision and Pilates 3June 2009 Mayo Clinic Women's HealthSource Highlights Summer Skin Problems, Low Vision and Pilates 4June 2009 Mayo Clinic Women's HealthSource Highlights Summer Skin Problems, Low Vision and Pilates 5
(Date:7/11/2014)... (PRWEB) July 11, 2014 The American ... America’s 55 poison centers are commending Senator Bill Nelson ... Prevention Act of 2014 on July 10, 2014. Along ... Consumer Products Safety Commission (CPSC) to enact rules requiring ... consumers. , Senate co-sponsors of the bill ...
(Date:7/11/2014)... Ticket Down reports that tickets to the ... place World Cup Match between Brazil and Netherlands ... place on Saturday, July 12th at Estadio Nacional de Brasilia ... take place on Sunday, July 13th at Estadio Jornalista Mario ... for the 2014 World Cup are guaranteed to be authentic ...
(Date:7/11/2014)... 11, 2014 Butler Mobility has recently updated ... Platform Lifts . Previously the two standard colors were ... beautiful earth tone colors as standard colors at no additional ... the home but will enhance the beauty of the stairway. ... home color scheme or individual décor. , The new selection ...
(Date:7/11/2014)... (HealthDay News) -- People with the lowest incomes may have ... disease (PAD), a new study suggests. People with PAD ... limbs, most often the legs. The condition causes leg pain ... throughout the body. People with PAD have a higher risk ... nearly 6,800 people with PAD who took part in the ...
(Date:7/11/2014)... 11, 2014 Volunteers from Scientology ... abuse this week with drug education lectures, forums and ... distribution in cities around the world. , Drug abuse ... Institute on Drug Abuse, abuse of alcohol and illicit ... crime, lost work, decreased productivity and healthcare. , ...
Breaking Medicine News(10 mins):Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3
... ... measuring and ultimately eliminating pain , ... Washington, DC (Vocus) June 4, 2010 -- Children’s National Medical Center ... the Sheikh Zayed Institute for Pediatric Surgical Innovation. Dr. Quezado joins a team of ...
... researchers say , FRIDAY, June 4 (HealthDay News) ... Wii Sports -- may help overweight seniors become more ... Although not an improvement on real-life gaming and sports ... offer a good alternative for those older individuals for ...
... Device includes ,carbon nanotubes, injected under skin, say researchers ... future, people with diabetes may be able to monitor ... This new type of continuous glucose monitor relies on ... blood sugar levels with a watch-sized or smaller monitor ...
... , ... BP to reach out for help, said Golden Age Resources, Inc. (GDAR) CFO Graham Larmer. ... Hollywood, FL (PRWEB) June ... alliance partner, Cobra Technologies, announced today the hiring of Geometrix Engineering, Inc. of Hollywood, FL ...
... so rampant last spring, will adopt a regular fall/winter pattern, ... year ago, global alarm over the emergence of an unpredictable ... Headlines blared that thousands were becoming sick; face masks and ... store shelves. , So, where is H1N1 this spring? , ...
... Dogs ... only patented product invented by a professional dog trainer. Successfully used worldwide for nine ... (used with autistic children) and Acupressure to calm dogs. Susan Sharpe, inventor, also provides ... ...
Cached Medicine News:Health News:Former NIH Chief Joins Children's National Medical Center 2Health News:Former NIH Chief Joins Children's National Medical Center 3Health News:Wii Games Can Get Seniors Moving 2Health News:Glucose 'Tattoo' Could Track Blood Sugar Levels for Diabetics 2Health News:Glucose 'Tattoo' Could Track Blood Sugar Levels for Diabetics 3Health News:Gulf Oil Spill Goes from Disaster to Catastrophe 2Health News:A Year After Its Emergence, H1N1 Swine Flu Lingers 2Health News:A Year After Its Emergence, H1N1 Swine Flu Lingers 3Health News:A Year After Its Emergence, H1N1 Swine Flu Lingers 4Health News:End Thunderstorm and Fireworks Fear with The Original Anxiety Wrap 2Health News:End Thunderstorm and Fireworks Fear with The Original Anxiety Wrap 3Health News:End Thunderstorm and Fireworks Fear with The Original Anxiety Wrap 4
... eliminate false signals and contamination caused ... Promega Barrier Tips offer performance and ... acids (PCR(a)), radioactive isotopes, tissue culture ... specimens. , ,Promega Barrier Tips are ...
... tips eliminate false signals and contamination ... tested, Promega Barrier Tips offer performance ... nucleic acids (PCR(a)), radioactive isotopes, tissue ... serological specimens. , ,Promega Barrier Tips ...
... AvantGard Low Binding 0.5l - 10l Eppendorf ... binding technology that significantly reduces the amount of ... other filter tips are advertised as low retention, ... adhering to the pipet tip. However, AvantGard also ...
10 L, Racked, Filtered, Pre-sterilized, 96 tips/rack Recommended for 2, 5 and 10 L pipettes....
Medicine Products: